Literature DB >> 19604234

Advances in the management and monitoring of extranodal NK/T-cell lymphoma, nasal type.

Raymond Liang1.   

Abstract

Extranodal natural killer (NK)/T-cell lymphoma, nasal type, has a unique geographic distribution. Its pathology is characterized by marked angio-invasion and tissue necrosis. A typical NK-cell phenotype is usually present: CD2(+), CD3 epsilon+, CD56(+), cytotoxic molecules+ and Epstein-Barr virus (EBV)+. Magnetic Resonance Imaging helps to clearly define the local involvement. Positron Emission Tomography helps to demonstrate system spread. Various prognostic variables (International Prognostic Index or the Korean Prognostic Index) should be documented. This may include quantification of plasma EBV DNA. For localized nasal disease, radiotherapy is important, although chemotherapy is often added. Sustainable remission is observed in over half of these patients. For extra-nasal or disseminated disease, systemic chemotherapy becomes the mainstay and the prognosis is usually poor. Doxorubicin-containing regimens are not entirely satisfactory and L-asparaginase containing regimens are being investigated. Patients with poor prognostic features may be considered for an early autologous haematopoietic stem cell transplant. Allogeneic transplantation is efficacious but is associated with high transplant-related mortality.

Entities:  

Mesh:

Year:  2009        PMID: 19604234     DOI: 10.1111/j.1365-2141.2009.07802.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  24 in total

Review 1.  Epstein-Barr Virus-associated lymphoproliferative disorders: experimental and clinical developments.

Authors:  Lingyun Geng; Xin Wang
Journal:  Int J Clin Exp Med       Date:  2015-09-15

Review 2.  Extranodal NK/T Cell Lymphoma, Nasal Type (ENKTL-NT): An Update on Epidemiology, Clinical Presentation, and Natural History in North American and European Cases.

Authors:  Bradley M Haverkos; Zenggang Pan; Alejandro A Gru; Aharon G Freud; Rachel Rabinovitch; Meng Xu-Welliver; Brad Otto; Carlos Barrionuevo; Robert A Baiocchi; Rosemary Rochford; Pierluigi Porcu
Journal:  Curr Hematol Malig Rep       Date:  2016-12       Impact factor: 3.952

3.  The clinical study of extranodal natural killer cell lymphoma, nasal type.

Authors:  Wei Gui; Zhiqiang Zhao; Quanliang Shen; Tong Wang; Bin Yang; Jianxia He; Xi Li; Shuling Hou; Li Zhang; Qiaohua Zhang; Liping Su
Journal:  Med Oncol       Date:  2010-12-03       Impact factor: 3.064

Review 4.  Treatment of localized extranodal NK/T cell lymphoma, nasal type.

Authors:  Seok Jin Kim; Won Seog Kim
Journal:  Int J Hematol       Date:  2010-11-18       Impact factor: 2.490

Review 5.  Current and future management of NK/T-cell lymphoma based on clinical trials.

Authors:  Motoko Yamaguchi
Journal:  Int J Hematol       Date:  2012-10-17       Impact factor: 2.490

Review 6.  Epstein-barr virus and the pathogenesis of T and NK lymphoma: a mystery unsolved.

Authors:  Lindsay C George; Martin Rowe; Christopher P Fox
Journal:  Curr Hematol Malig Rep       Date:  2012-12       Impact factor: 3.952

7.  Reconstruction of a rare palate defect originating from extranodal natural killer/t-cell lymphoma.

Authors:  So-Eun Han; So Young Lim
Journal:  Arch Plast Surg       Date:  2013-05-16

8.  Extranodal natural-killer/t-cell lymphoma, nasal type.

Authors:  Harinder Gill; Raymond H S Liang; Eric Tse
Journal:  Adv Hematol       Date:  2010-12-30

9.  PET/CT aids the staging of and radiotherapy planning for early-stage extranodal natural killer/T-cell lymphoma, nasal type: a case series.

Authors:  Shannon L MacDonald; Liam Mulroy; Derek R Wilke; Steven Burrell
Journal:  Radiat Oncol       Date:  2011-12-30       Impact factor: 3.481

10.  Extranodal natural killer/T-cell lymphoma, nasal type: 'midline lethal granuloma.' A case report.

Authors:  Martha M Tlholoe; Monica Kotu; Razia A G Khammissa; Meschack Bida; Johan Lemmer; Liviu Feller
Journal:  Head Face Med       Date:  2013-01-17       Impact factor: 2.151

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.